o:2951 JAK-Inhibitors - A Story of Success and Adverse Events en Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Protein-Tyrosine Kinase; Rheumatoid-Arthritis; Interferon-Alpha/Beta; Cardiovascular Events; Psoriatic-Arthritis; Cancer-Risk; Tofacitinib; Metaanalysis; Mortality; Inflammation 1552099 10.2147/OARRR.S436637 2024-05-07T13:15:56.561Z 44 yes 46 Rebekka Wlassits Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie Mathias Müller University of Veterinary Medicine Vienna person 0000-0002-7879-3552 Karl H. Fenzl Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie person Thomas Lamprecht Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie person Ludwig Erlacher Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie person application/pdf 440813 https://phaidra.vetmeduni.ac.at/o:2951 no yes 17 70 1552253 Open Access Rheumatology - Research and Reviews 11 16 43 53 Dove Medical Press Ltd 2024